45 Healthcare Resource Utilization and Costs Among Patients Receiving Cangrelor or Glycoprotein IIb/IIIa Inhibitors During Percutaneous Coronary Intervention in the United States | Synapse
March 31, 2026
45 Healthcare Resource Utilization and Costs Among Patients Receiving Cangrelor or Glycoprotein IIb/IIIa Inhibitors During Percutaneous Coronary Intervention in the United States
Puntos clave
Los puntos clave no están disponibles para este artículo en este momento.